Disease area strategy that ranks the indications worth backing.

Disease area strategy is the choice of which diseases, indications and patient segments a pharma or biotech company will invest in, and which it will leave to others. The strategy weighs each option on unmet need, feasibility and competitive intensity before capital is committed. Nextyn builds the evidence from interviews with KOLs and payers, alongside market data, so each ranking can be defended in a portfolio review. Nextyn sends a research plan within 48 hours of the brief.

A Nextyn therapy area opportunity assessment delivers three outputs: a ranked list of indications and segments, need, feasibility and competition ratings for each, and the evidence behind every ranking. Each output comes from primary interviews with KOLs and payers, set against market data:

• Ranked opportunities: the indications and patient segments in order of strategic potential
• Ratings: unmet need, feasibility and competitive intensity, rated for each opportunity
• Evidence summary: the expert and payer views behind each position, ready for a portfolio review

Nextyn interviews the three groups whose judgment decides whether an opportunity is real: key opinion leaders, treating physicians and payers. Together the three groups show where need is unmet, whether a therapy can reach patients, and whether it would be covered:

• Key opinion leaders, on unmet need and where the science is heading
• Treating physicians, on priority patient segments and current treatment gaps
• Payers and HTA decision-makers, on access prospects for each opportunity

Nextyn runs disease area strategy research in the United States, the United Kingdom, Germany, France, Italy and Spain, among other markets. Markets are agreed at scoping and weighted to where the company plans to launch, because need, access and competition differ by country. Recent Nextyn work includes KOL and payer interviews in Spain that assessed unmet need, priority patient segments and feasibility across the immunology landscape to set indication priorities.

Nextyn recommends disease area strategy research before capital is committed to a new indication, a new therapy area or an expansion of an existing franchise. At that point the evidence decides where development money goes, instead of explaining a choice that has already been made. There are three other triggers for a fresh ranking: a portfolio review, a pipeline setback and a competitor entering the space.

A Nextyn disease area strategy project runs in four steps, from brief to read-out, and nothing is commissioned until the client approves the plan. The client sees the sample, method and price before any fieldwork, and reads every interview with the Nextyn team at the end.

1. Submit the brief: the disease area, the options under review, the markets and the portfolio decision to settle.
2. Receive a plan within 48 hours: which KOLs, physicians and payers Nextyn will interview, how, and what the work costs.
3. Approve the plan: fieldwork starts only after sign-off.
4. Review the read-out: every interview read together, showing where experts and payers agree, where they conflict and what is still open.

Nextyn sends a research plan within 48 hours of receiving the brief, stating who will be interviewed, how, and what the work costs. The plan sets the fieldwork length for the number of opportunities and markets in scope, so a focused comparison of three indications and a full therapy-area scan each get their own timeline. Nothing is commissioned until the client approves that plan and its price.

Nextyn's disease area strategy ranks a company's options against each other on unmet need, feasibility and competition, while a market sizing report puts a value on each market for every subscriber. Sizing shows how big a space is, and the strategy shows which spaces one company should enter and why the alternatives ranked lower.